GET DAILY SIGNALSHCA Healthcare (HCA) Climbs +8% in Recent Weeks on Resilient Volumes
Key Takeaways
- HCA Healthcare shares have advanced roughly 8% over the trailing 30 days, a steady climb that leaves the stock well above its 52-week low of about $354 and below its 52-week high near $556.
- As of late October 2026, HCA traded around $472 per share, with a market capitalization of approximately $101 billion and a price-to-earnings ratio in the mid-teens.
- Second-quarter 2026 results came in ahead of consensus, with revenue of $20.23 billion and diluted earnings per share of $7.59, up 11% year over year.
- Management revised full-year 2026 guidance to revenue of $77.0–$79.5 billion and diluted EPS of $28.70–$30.50, reflecting payer-mix pressure from the expiration of enhanced premium tax credits.
- Several firms have turned more constructive on the shares, including RBC Capital (Outperform, $496 target), TD Cowen (Buy, $460), and BMO Capital (Outperform, $495).
- For more detail, explore HCA's Price Targets, Earnings, and Forecast pages.
- Discover top-performing automated strategies on Trending AI Robots.
Market Snapshot
HCA Healthcare's stock has moved steadily higher in recent weeks, gaining about 8% over the past 30 days on resilient hospital volumes and improving investor sentiment toward healthcare services. The shares remain in a broad recovery range, with a 52-week span of roughly $354 to $557. The company carries a trailing dividend yield near 0.7% and a beta of about 1.1, indicating slightly above-market volatility relative to the broader equity market. Analysts broadly rate the stock a Buy, with an average 12-month price target near $460, though several recently raised targets sit meaningfully higher. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Business Overview and Competitive Position
HCA Healthcare is the largest for-profit hospital operator in the United States. Headquartered in Nashville, Tennessee, the company operates approximately 190 hospitals and roughly 2,600 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers, and physician clinics, across 19 states and the United Kingdom. Its scale gives HCA meaningful cost advantages over smaller and not-for-profit rivals, supporting industry-leading operating margins.
The company benefits from long-term demographic tailwinds, including an aging population that consumes more healthcare services, and maintains strong local positions in faster-growing markets such as Florida and Texas. HCA complements its acute-care footprint with a large outpatient network and a multi-billion-dollar capital expenditure program aimed at adding inpatient beds and ambulatory capacity. It also returns capital to shareholders through dividends and share repurchases.
Recent Developments and Earnings
HCA's second-quarter 2026 report, released in late July, set the tone for the recent advance. Revenue rose 8.7% year over year to $20.23 billion, and diluted EPS climbed 11% to $7.59, both beating consensus estimates. Same-facility admissions and equivalent admissions increased 2.5% and 2.7%, respectively, while emergency room visits rose 3.6%, underscoring durable underlying demand.
The dominant headwind remains the expiration of enhanced premium tax credits, which reduced health-insurance-exchange enrollment and increased the number of uninsured patients. Management now expects an unfavorable exchange-related impact on adjusted EBITDA of roughly $1.0 billion to $1.2 billion for 2026, partially offset by incremental Medicaid supplemental payment benefits of $300 million to $500 million, including a Florida directed payment program.
Against that backdrop, analyst sentiment has improved. RBC Capital raised its price target to $496 from $435 with an Outperform rating, TD Cowen lifted its target to $460 from $431 with a Buy rating, and BMO Capital initiated coverage with an Outperform rating and a $495 target. HCA's third-quarter 2026 results are scheduled for late October, giving investors a fresh look at volume trends and cost discipline.
2026 Outlook and Key Factors to Monitor
Looking ahead, investors will focus on several factors. First, HCA's third-quarter results will provide clarity on whether resilient demand is offsetting the exchange-driven payer-mix shift. Management expects stronger adjusted EBITDA growth in the fourth quarter relative to the third, so commentary on that trajectory will be closely watched.
Policy developments also matter. Potential changes to Medicaid eligibility, work requirements, and supplemental payment programs could influence reimbursement, and HCA has indicated it is preparing through litigation and patient support. Elective surgery volumes, which have lagged emergency procedures, remain a key swing factor, as do labor costs, inflation, and interest rates. Finally, the company's cost-resiliency program, AI-enabled efficiency initiatives, and multi-billion-dollar capacity expansion will shape margins and long-term growth. These dynamics, rather than any single catalyst, are likely to drive HCA's performance through 2026.
Using AI Tools for Strategy Discovery
In my analysis of stocks like HCA, I often turn to Tickeron’s automated tools to compare performance across strategies. The Trending AI Robots section highlights a curated selection of the platform's top-performing automated trading strategies. While Tickeron offers hundreds of AI trading bots covering thousands of tickers, only the top-performing and most relevant bots appear in this featured section. These bots vary by strategy, timeframe, and performance metrics, allowing users to compare approaches across different market conditions. The page is designed to help traders and investors discover data-driven, rules-based systems rather than relying solely on discretionary decision-making. For those interested in exploring automated trading tools, Trending AI Robots offers a practical starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
HCA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for HCA turned positive on October 08, 2026. Looking at past instances where HCA's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 07, 2026. You may want to consider a long position or call options on HCA as a result. In 64 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
Following a +2.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where HCA advanced for three days, in 247 of 348 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 206 of 322 cases where HCA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for HCA moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 49 similar instances where the indicator moved out of overbought territory. In 33 of the 49 cases, the stock moved lower in the following days. This puts the odds of a move lower at 67%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 66 cases where HCA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 55%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
HCA broke above its upper Bollinger Band on October 14, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 23 (best 1 - 100 worst), indicating outstanding price growth. HCA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-15.288) is normal, around the industry mean (204.136). P/E Ratio (15.521) is within average values for comparable stocks, (19.375). Projected Growth (PEG Ratio) (1.323) is also within normal values, averaging (2.498). Dividend Yield (0.007) settles around the average of (0.098) among similar stocks. P/S Ratio (1.264) is also within normal values, averaging (2.688).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of health care services
Industry HospitalNursingManagement
Advertisement